ASH 2019 | Should we act therapeutically on MRD positivity in AML?

Name: Should we act therapeutically on MRD positivity in AML?
Uploaded: 2019-12-07T00:00:00.000Z
Duration: 2 min 20 s
Description: Christoph Röllig, MD, MSc, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the measurement of residual disease in acute myeloid leukemia (AML), and the question of whether we should act therapeutically on MRD positivity in AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Christoph Röllig • 7 Dec 2019

ASH 2019

Acute Myeloid Leukemia Leukemia Azacitidine

Christoph Röllig, MD, MSc, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the measurement of residual disease in acute myeloid leukemia (AML), and the question of whether we should act therapeutically on MRD positivity in AML. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.